☆ 4.6 Letter

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 185, Issue 1, Pages 193-197

Publisher

WILEY
DOI: 10.1111/bjh.15440

Keywords

richter syndrome; ibrutinib; idelalisib; lenalidomide; chronic lymphocytic leukaemia

Categories

Hematology

Funding

  1. A.I.R.C. projects [IG-15397]
  2. Gilead Fellowship Program 2017
  3. Ministero dell'Istruzione dell'Universita e della Ricerca
  4. AIRC Regional Project
  5. Fondazione CARIPARO
  6. Fondazione CARIVERONA
  7. Regione Veneto on chronic lymphocytic leukaemia
  8. University of Padua - ONLUS Ricerca per Credere nella Vita

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.